53P Second-line treatment in advanced non-squamous (NS) non-small cell lung cancer (NSCLC) patients in Spain, analyzed in the Thoracic Tumor Registry (RTT)

Abstract

Non-small cell lung cancer (NSCLC) accounts for the vast majority of all diagnosed lung cancers. From a histological point of view, approximately 70% to 78% of NSCLC are considered non-squamous (NS). Our analysis aimed to describe the clinical, epidemiological characteristics and survival of Spanish patients suffering from advanced NS NSCLC, treated in second line included in the RTT of the Spanish Group of Lung Cancer. 2342 patients with advanced NS NSCLC in second line were included. The median age was 67 years. 63.4 % were men. 97% of them were White. 41.7% were former smokers and 35.7% were active smokers. ECOG performance status was 0 in 32.2% and 1 in 58.7%. Most common site of metastasis was lung in 41.7%, bone in 36%, and adrenal glands in 15.6% of patients. In overall population a median progression-free survival (PFS) time of 8.1 months (4.7-13.5 m) was observed. A median overall survival (OS) time of 22.1 m (11.6-45.8 m) A total of 145 (5.8%) patients had been treated with nintedanib (N). The median PFS for patients with N treatment was 8.3 months (5.6 - 16.2 months) and for patients without was 8.1 months (4.7 - 13.5). The probability of PFS at 6, 12 and 24 m was 66.1% (64.0% - 68.0%), 29.8% (27.8% - 31.7%) and 8.2% (7.1% - 9.4%), respectively, in patients without N treatment, and 70.8% (62.4% - 77.7%), 32.8% (25.1% - 40.7%) and 11.7% (8.0% - 17.7%) in patients with N treatment. The median OS with N was 22.4 m (13.5-39.5 m) and for patients without was 22.1 m (11.6 - 45.8 m). The OS at 6, 12 and 24 m was 98.6% (94.5% - 99.6%), 80.7% (73.2% - 86.4%) and 45.5% (36.9% - 53.7%), respectively in patients with N and 93.2% (92.0% - 94.1%), 73.9% (72.0% - 75.7%), and 47.1% (44.9% - 49.3%) in patients without. The results of our analysis described the largest and most comprehensive series of NS NSCLC in the European population. Most patients included in the analysis were men and former or current smokers. The survival probability at 6, 12 and 24 months is slightly better in patients treated with nintedanib versus the overall population.